The new share issue will increase the number of shares in Active Biotech by 4 million to 44 million shares.
Active Biotech's new share issue will be completed in accordance with the following timetable:
|
Notification of possible allocation of shares subscribed for without
the support of subscription rights |
Around February 15, 2007 |
|
Last day of payment for shares allocated based on subscription without
the support of subscription rights |
Around February 20, 2007 |
|
First day of trading in new shares |
Around February 26, 2007 |
The conversion price for existing convertible debentures issued in December 2004 will be recalculated as a consequence of the share issue currently being implemented, and will thereafter amount to SEK 37.42.
Lund, February 14, 2007
Active Biotech AB (publ)
Sven Andréasson
President & CEO
For further information, please contact:
Sven Andréasson, President & CEO, tel. +46 46-19 20 49
Hans Kolam, CFO, tel. +46 46-19 20 44
Cecilia Hofvander, Manager Corporate Communications, tel. +46 46-19 11 22
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.
Active Biotech AB (org.nr 556223-9227)
P.O. Box 724, SE-220 07 Lund, Sweden
Tel +46 46 19 20 00
Fax +46 46 19 20 50